Agent [reference] | AITL (no.) | ORR/CR (%) | Median PFS (months) |
---|
Romidepsin [15] | 27 | 30/19 | 4 |
Pralatrexate [16] | 13 | 8/NR | 3.5 |
Bendamustine [17] | 32 | NR | 3.6 |
Brentuximab vedotin [18] | 13 | 54/38 | 2.6 |
Lenalidomide [19] | 7 | 29/0 | 3.2 |
CHOP [20] | 33 | NR/61 | 26 |
- Abbreviations: AITL Angioimmunoblastic T-cell lymphoma, CR Complete response, ORR Overall response rate, PFS Progression-free survival